Evaxion CEO kommentiert strategische Ausrichtung
November 14, 2022 05:31 ET
|
Evaxion Biotech
KOPENHAGEN, Dänemark, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion" oder das „Unternehmen“), ein Biotechnologieunternehmen im klinischen Stadium, das sich auf...
Le PDG d'Evaxion commente l'orientation stratégique du groupe
November 14, 2022 05:31 ET
|
Evaxion Biotech
COPENHAGUE, Danemark, 14 nov. 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie clinique spécialisée dans le développement...
Evaxion CEO comments on strategic focus
November 10, 2022 04:10 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion begrüßt Per Norlén als neuen CEO
October 06, 2022 07:58 ET
|
Evaxion Biotech
KOPENHAGEN, Dänemark, Oct. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein Biotechnologieunternehmen in der klinischen Phase, das sich...
Evaxion accueille Per Norlén au poste de nouveau PDG
October 06, 2022 07:58 ET
|
Evaxion Biotech
COPENHAGUE, Danemark, 06 oct. 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX) (« Evaxion » ou la « Société »), une société de biotechnologie au stade clinique spécialisée dans le...
Evaxion welcomes Per Norlén as new CEO.
October 05, 2022 08:32 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy
September 21, 2022 05:45 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...
Evaxion Announces NIH Grant for Research Collaboration With UMass Chan Medical School
September 06, 2022 07:02 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), announced today that the Company, in collaboration with UMass Chan Medical...
Evaxion Biotech Announces Second Quarter 2022 Financial Results and Provides Business Update
August 10, 2022 07:00 ET
|
Evaxion Biotech
Expanded DNA oncology vaccine program into non-small cell lung cancer, NSCLCAnnounced successful production of personalized cancer immunotherapies for melanomaAnnounced gonorrhea as second bacterial...
Evaxion Biotech A/S Announces Executive Management Changes
August 02, 2022 07:00 ET
|
Evaxion Biotech
COPENHAGEN, Denmark, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of...